Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen-primed DC Vaccine in Refractory NSCLC
NCT02956551Phase 1Unknown
- Sponsor
- Sichuan University
- Start
- Nov 2016
- Primary completion
- Dec 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neoantigen-primed dendritic cell vaccine in non-small cell lung cancer (NSCLC), sponsored by Sichuan University. Primary endpoint: Number of participants with treatment-related adverse events. Status: unknown.
02
Drugs
neoantigen-primed dendritic cell vaccine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02956551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956551.